Insider Transactions in Q1 2025 at Kymera Therapeutics, Inc. (KYMR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,740
-2.3%
|
$172,200
$30.67 P/Share
|
|
Mar 03
2025
|
Jared Gollob Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.26%
|
-
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,035
-1.69%
|
$211,050
$30.67 P/Share
|
|
Mar 03
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+12.56%
|
-
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,383
-1.0%
|
$41,490
$30.67 P/Share
|
|
Mar 03
2025
|
Jeremy G Chadwick Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+26.54%
|
-
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,241
-1.37%
|
$67,230
$30.67 P/Share
|
|
Mar 03
2025
|
Ellen Chiniara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+25.04%
|
-
|
|
Jan 10
2025
|
Bruce N. Jacobs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.29%
|
$20,000
$2.08 P/Share
|
|
Jan 10
2025
|
Nello Mainolfi Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.49%
|
$20,000
$2.08 P/Share
|
|
Jan 06
2025
|
Ellen Chiniara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,129
-5.4%
|
$128,289
$41.75 P/Share
|